Breaking News
February 23, 2018 - Tobacco Kills, No Matter How It’s Smoked: Study
February 23, 2018 - Q&A: Avindra Nath, MD | Medpage Today
February 23, 2018 - Adherence to sleep apnea treatment affects risk of hospital readmission
February 23, 2018 - Zika virus could be alternative for treatment of aggressive brain cancer
February 23, 2018 - Carbon monoxide enhances efficacy of antibiotic against stomach infection
February 23, 2018 - MSD and Ferring Pharmaceuticals Complete Largest Ever Clinical Trial in Postpartum Haemorrhage
February 23, 2018 - Postnova AF2000 system offers reliable characterization of trace metal colloid distribution in the environment
February 23, 2018 - Pioneering study may pave way for effective painkillers to treat neuropathic pain
February 23, 2018 - Research opens up new avenue to minimize risks of transplants
February 22, 2018 - Cabozantinib Active in Advanced Thyroid Cancer
February 22, 2018 - Polluted air may pollute our morality
February 22, 2018 - New data from VOYAGE 2 trial shows promising results for Janssen’s guselkumab treatment
February 22, 2018 - Bank loans signed in the hospital leave patients vulnerable
February 22, 2018 - Researchers identify new nanostructure inside sperm tails
February 22, 2018 - Catheter-based procedure increases treatment options for mitral valve disease
February 22, 2018 - Sage Therapeutics Receives FDA Breakthrough Therapy Designation for SAGE-217 for the Treatment of Major Depressive Disorder
February 22, 2018 - Larger Endocarditis Vegetations More Likely to Embolize, Kill
February 22, 2018 - Parenting behavior in adoptive families
February 22, 2018 - Researchers discover new weakness in sleeping sickness parasites
February 22, 2018 - Research project aims to find new ways to identify and treat most aggressive brain cancers
February 22, 2018 - Researchers explore how people with Alzheimer’s disease use end-of-life medical services
February 22, 2018 - Stroke survivors and carers feel marginalized due to lack of support from primary care
February 22, 2018 - Neuroscientists discover novel mechanism of action behind schizophrenia
February 22, 2018 - After shooting, ‘honor how kids want to deal with their feelings’
February 22, 2018 - U.S., EU and Japan Health Authorities Accept Regulatory Submissions For Review Of Pfizer’s Third-generation ALK Inhibitor Lorlatinib
February 22, 2018 - At-Home Genetic Test Might Change Medicine
February 22, 2018 - Many second hand plastic toys could pose a risk to children’s health, study suggests
February 22, 2018 - Study shows that two different brain systems cooperate during learning
February 22, 2018 - Liquefied brain tissue after stroke may harm surviving brain, UA study finds
February 22, 2018 - New intervention improves communication behaviors in couples affected by dementia
February 22, 2018 - Clinical trial shows safety of promising TSRI stroke drug
February 22, 2018 - Researchers discover new interaction mechanism of unstructured proteins
February 22, 2018 - A Patient’s Journey: Can I Kill the Glucose Monster?
February 22, 2018 - The Problem That Piles Up
February 22, 2018 - Kids can roll up their sleeves—again—for mumps protection
February 22, 2018 - Scientists find significant amounts of toxic metals in e-cigarette vapors
February 22, 2018 - 3D Signatures reports positive results of new Telo-HL test for Hodgkin’s lymphoma
February 22, 2018 - Scientists reveal development of improved medicine to fight addiction
February 22, 2018 - USC-led researchers release dataset of brain scans from stroke patients
February 22, 2018 - Antibiotic-producing bacterium releases more metabolites than assumed
February 22, 2018 - Flu Season Shows First Signs of Slowing
February 22, 2018 - Nonstick Chemicals May Disrupt Metabolic Function in Women
February 22, 2018 - Calcium may play a role in the development of Parkinson’s disease
February 22, 2018 - Scientists visualize insulin receptor activation for the first time
February 22, 2018 - UC San Diego Health now offers new treatment option for people with refractory epilepsy
February 22, 2018 - First African child vaccinated with new typhoid conjugate vaccine
February 22, 2018 - BetterYou named as ‘Most Innovative Brand’ at FGB Awards 2018
February 22, 2018 - Assaults Among Young People Fall to Lowest Rate in 15 Years
February 22, 2018 - What do you know about Parkinson’s disease?
February 22, 2018 - Researchers discover five new genetic changes that may increase pancreatic cancer risk
February 22, 2018 - Gout medication may help improve heart function in adult patients
February 22, 2018 - Bioactive compound limits collateral damage in the kidneys after heart attack
February 22, 2018 - Study reveals HCT as effective treatment for NHL patients regardless of age
February 22, 2018 - Father’s age can affect offspring lifespan, mice study shows
February 22, 2018 - Opiant Pharmaceuticals Announces Publication of New Pre-Clinical Data Supporting Potential of OPNT005 as a Heroin Vaccine
February 22, 2018 - Make the Diagnosis: Strange Rash Surfaces
February 22, 2018 - Isolated sulfite oxidase deficiency – Genetics Home Reference
February 22, 2018 - Scientists identify weight loss ripple effect
February 22, 2018 - Smoking at record lows in New York
February 22, 2018 - Scientists pinpoint fertility hormone that could support early pregnancy
February 22, 2018 - Aggressive cancer stem cells can now be isolated successfully in a scientific breakthrough
February 22, 2018 - Researchers find high risk of suicide among unaccompanied refugee minors
February 22, 2018 - Protein levels linked to posture and gait problems in Parkinson’s
February 22, 2018 - Biomedical engineers create 3D hydrogel scaffolds  to transform cells into muscle
February 22, 2018 - Study employs novel approach to uncover new biomarker for CHD
February 22, 2018 - Study finds strong connection between midwifery and birth outcomes
February 22, 2018 - Verastem Submits NDA to FDA for Duvelisib for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Follicular Lymphoma
February 22, 2018 - Low BP Associated With Risk in HFpEF
February 22, 2018 - More U.S. women obese before pregnancy, experts sound the alarm
February 22, 2018 - Study aims to examine effects of PTSD symptoms in police officers
February 22, 2018 - Study reveals increased disease risk after early heart surgery
February 22, 2018 - Women with Type 1 diabetes come across unique challenges
February 22, 2018 - Researchers target abnormal epigenetic mechanisms involved in childhood cancers
February 22, 2018 - Wine polyphenols may be good for oral health
February 22, 2018 - Moderate and severe exacerbations associated with decline in physical activity of COPD patients
February 22, 2018 - FDA Approves Osmolex ER (amantadine) for the treatment of Parkinson’s Disease and Drug-Induced Extrapyramidal Reactions
February 22, 2018 - Morning Break: NSCLC Approval; School Nurses; ‘Human-Sheep Hybrids’?
February 22, 2018 - Penn study sheds new light on immune cell identity
February 22, 2018 - From a novel support group to a book, learning from seven widowed fathers
February 22, 2018 - Researcher makes breakthrough discovery in process of fear relapse
Slow Medicine: Good Reads | Medpage Today

Slow Medicine: Good Reads | Medpage Today

image_pdfDownload PDFimage_print

We have known since the publication of the COURAGE trial in 2007 that percutaneous coronary intervention (PCI) does not reduce the risk of cardiovascular events among patients with stable angina. Interventional cardiologists, however, continue to recommend widespread use of these procedures on the basis that PCI may relieve symptoms of angina. In what will likely prove to be another landmark study on the topic, in the ORBITA trial – published recently in the Lancet — researchers randomized 230 patients with stable angina and at least 70% single vessel coronary stenosis who had been optimized on medical therapy to receive either a stent or a sham procedure. At 6 weeks of follow-up, patients in both groups had similar changes in their exercise capacity. While ORBITA was a small study, and may have been underpowered to detect small benefits to exercise capacity, these findings reinforce our current practice. We advocate lifestyle changes and medication therapy for most patients with stable coronary disease, reserving consideration of revascularization (either PCI or CABG) only for patients with severe persistent symptoms or certain specific findings (i.e., a markedly abnormal exercise stress test involving hypotension during stage 1 of the Bruce protocol, patients with left main stem coronary disease, or those with ejection fractions <30% since all of these were exclusion criteria in COURAGE and/or ORBITA). We hope this study's results will help bring others in the medical community in line with the Slow Medicine approach to stable angina.

Earlier this month, Milton Packer, MD, – co-principal investigator of the PARADIGM-HF trial (sacubitril/valsartan) and chair of the executive committee for the EMPEROR trial program (empagliflozin) — wrote a compelling MedPage Today perspective piece that has garnered widespread attention. In the piece, Packer describes speaking about recent advances in heart failure to a group of physicians who evaluate prior authorization requests for insurance companies. At the end of the talk, he asks his audience whether they were encouraged by the data he presented, and if they plan to begin authorizing the new medications like sacubitril/valsartan. He received an astonishing answer. One of the physicians explained: “Yes, you were very convincing. But the drugs are too expensive. So we typically reject requests, at least the first time. We figure that, if doctors are really serious, then they should be willing to make the request again and again … Plus, if I approve too many expensive drugs, I won’t get my bonus at the end of the month. So giving out too many approvals wouldn’t be a smart thing for me to do. Would it?” This story is of course disturbing, and we are disheartened – though not surprised – to learn the extent to which the drug approval process is influenced by the bottom line. But also disturbing (though perhaps not quite as appalling) are all the times in which unnecessary, ineffective, and potentially harmful therapies are approved by insurance companies. As we’ve previously written, too often new medications such as sacubitril/valsartan or empagliflozin are widely adopted in clinical practice before it is clear that their benefits outweigh the harms. While we find it disgraceful that physicians reviewing authorizing requests receive bonuses for denying medication requests, we believe there is a need for a general re-thinking of the utilization review process such that it better aligns with the evidence.

How should we incorporate nutrition counseling into our busy clinical practices? JoAnn Manson and a colleague discuss practical approaches for doing so in a recent JAMA Viewpoint. We particularly like their emphasis on small, sustainable steps and a team-based approach. While we might not have time to explore an individual’s dietary approach during each visit, we do try to use almost every visit as an opportunity to emphasize the relative importance of lifestyle changes compared to the medical interventions we have to offer.

According to important new research in JAMA, among women “without a history of infertility who had been trying to conceive for 3 months or less, biomarkers indicating diminished ovarian reserve compared with normal ovarian reserve were not associated with reduced fertility.” Writes the editorialist: “women who have never attempted to conceive should not be evaluated in a manner similar to those with infertility. Doing so can not only provide potentially misleading and anxiety-producing results but may also lead to costly fertility preservation treatments that have no value.”

Which patients with an ischemic stroke will benefit from closure of a patent foramen ovale (PFO) — a defect found in 25% of healthy people — remains an area of controversy. The authors of a recent NEJM perspective describe a thoughtful approach to making the decision: closure should only be pursued after consultation with both a cardiologist and a neurologist along with an extensive work-up for alternative etiologies.

A pair of studies in last month’s JAMA has shed light on the overly exuberant adoption of robotic surgery. The first study found that between 2003 and 2015, the use of robotic surgery for radical nephrectomy increased from 1.5% to 27%. This change was not associated with changes in surgical complications, however, it was associated with prolonged operating time with laparoscopic surgery. In the second study, the authors conducted an randomized controlled trial comparing robotic-assisted versus conventional laparoscopic surgery among patients undergoing resection for rectal cancer, and concluded that the robotic-assisted procedure “does not confer an advantage in rectal cancer resection.” An accompanying editorial concludes: “for procedures in which a minimally invasive laparoscopic procedure is already in use, there is often no meaningful incremental benefit in the use of robotic assistance in terms of complication rates or recovery. Importantly, in these scenarios, robotic-assisted operations are often associated with longer operating times.”

Canakinumab, a human monoclonal antibody against interleukin-1 beta, was recently found to have beneficial effects in patients with stable coronary artery disease in a major study in the NEJM. There are trade-offs, however, including life-threatening infections that merit serious pause, and we agree with the editorialist that more research is needed to determine when canakinumab is indicated for stable coronary heart disease.

As we have explained in our “Disruptions or Distractions” series, even intuitive care delivery interventions may not work as intended. This appears to have been the case for a care management program targeting nursing home residents that was evaluated in JAMA Internal Medicine. The program involved several strategies, including helping nursing home staff be more systematic about identifying acute changes in their patients and promoting advanced care planning. The analysis found no impact on emergency room and hospitalization rates among the nursing home residents. Similarly, a recent systematic review in the Journal of General Internal Medicine concluded that primary care interventions focused on high-need, high-cost patients do not consistently prevent subsequent hospital utilization nor do they uniformly improve outcomes. As Stanford professor Steve Asch put it in a piece we wrote last year on the topic, “because so few controlled trials have been undertaken” on programs targeting high risk patients, “the jury is still out” regarding what works.

A new study in JAMA has found, disappointingly, that sertraline is ineffective for major depressive disorder among patients with non-dialysis-dependent chronic kidney disease. This finding comes in the wake of mounting evidence that many therapies found to work in the general population may be ineffective among patients with chronic kidney disease. For example, research has failed to demonstrate a benefit of statins in patients undergoing dialysis. Research has also raised questions about the value of SSRIs among patients with other chronic conditions, such as heart failure. These findings are noteworthy because use of antidepressants and statins are common among patients with CKD and heart failure, yet it now appears these therapies may not be broadly effective in these populations. More generally, it highlights the importance of rigorously assessing therapies in different populations. Just because an approach works in one population does not guarantee it will work in another.

Finally, a JAMA case report highlights the potential value of using a “patient safety framework” for addressing the problem of overuse in healthcare. According to the editorialist, the National Academy of Medicine includes underuse, misuse, and overuse as part of their framework for assessing quality and safety. To date, however, the lion’s share of quality improvement work has emphasized underuse and misuse. Perhaps it’s time to begin tackling the problem of overuse with this same resolve.

“Updates in Slow Medicine” applies the latest medical research to support a thoughtful approach to clinical care. It is produced by Pieter Cohen, MD, of Harvard Medical School, and Michael Hochman, MD, MPH, of the Keck School of Medicine at the University of Southern California. To learn more, visit their website.


Tagged with:

About author

Related Articles